CA1341314C
(en)
|
1984-07-06 |
2001-11-06 |
David Cox |
Derivatives of benzimidazole, benzothiazole and benzoxazole
|
US6749864B2
(en)
*
|
1986-02-13 |
2004-06-15 |
Takeda Chemical Industries, Ltd. |
Stabilized pharmaceutical composition
|
US5433959A
(en)
|
1986-02-13 |
1995-07-18 |
Takeda Chemical Industries, Ltd. |
Stabilized pharmaceutical composition
|
CA1327010C
(en)
*
|
1986-02-13 |
1994-02-15 |
Tadashi Makino |
Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
|
CA1276017C
(en)
*
|
1986-02-13 |
1990-11-06 |
Takeda Chemical Industries, Ltd. |
Sulfenamide derivatives and their production
|
DK171989B1
(da)
*
|
1987-08-04 |
1997-09-08 |
Takeda Chemical Industries Ltd |
Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
|
AU3690289A
(en)
*
|
1988-05-25 |
1989-12-12 |
Byk Gulden Lomberg Chemische Fabrik Gmbh |
New fluoralkoxy compounds
|
JP2536173B2
(ja)
*
|
1988-08-18 |
1996-09-18 |
武田薬品工業株式会社 |
注射剤
|
US5223515A
(en)
*
|
1988-08-18 |
1993-06-29 |
Takeda Chemical Industries, Ltd. |
Injectable solution containing a pyridyl methylsulfinylbenzimidazole
|
AT391693B
(de)
*
|
1988-11-15 |
1990-11-12 |
Cl Pharma |
Verfahren zur herstellung von 3-5-dimethyl-4methoxypyridinderivaten sowie neues zwischenprodukt hierfuer
|
SE8804629D0
(sv)
|
1988-12-22 |
1988-12-22 |
Ab Haessle |
New therapeutically active compounds
|
SE8804628D0
(sv)
|
1988-12-22 |
1988-12-22 |
Ab Haessle |
New compounds
|
IE64199B1
(en)
*
|
1988-12-22 |
1995-07-12 |
Haessle Ab |
Compound with gastric acid inhibitory effect and process for its preparation
|
DE69014141T2
(de)
*
|
1989-02-10 |
1995-05-24 |
Takeda Chemical Industries Ltd |
Verwendung von Benzimidazol-Derivaten als antibakterielle Mittel.
|
US5274099A
(en)
*
|
1989-12-20 |
1993-12-28 |
Aktiebolaget Hassle |
Therapeutically active fluoro substituted benzimidazoles
|
US4965269A
(en)
*
|
1989-12-20 |
1990-10-23 |
Ab Hassle |
Therapeutically active chloro substituted benzimidazoles
|
US5049674A
(en)
*
|
1989-12-20 |
1991-09-17 |
Aktiebolaget Hassle |
Therapeutically active fluoro substituted benzimidazoles
|
DE69132082T2
(de)
|
1990-10-17 |
2000-08-31 |
Takeda Chemical Industries, Ltd. |
Pyridin-Derivate, Verfahren zu deren Herstellung und Anwendung
|
TW209174B
(instruction)
|
1991-04-19 |
1993-07-11 |
Takeda Pharm Industry Co Ltd |
|
NZ244301A
(en)
*
|
1991-09-20 |
1994-08-26 |
Merck & Co Inc |
Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds
|
ES2036948B1
(es)
*
|
1991-11-21 |
1994-09-01 |
Genesis Para La Investigacion |
Procedimiento de obtencion de compuestos derivados de piridina.
|
WO1994001107A1
(en)
*
|
1992-07-08 |
1994-01-20 |
Monsanto Company |
Benzimidazoles for alleviating stomach ulcers in swine
|
US5589491A
(en)
*
|
1992-07-28 |
1996-12-31 |
Astra Aktiebolag |
Injection and injection kit containing omeprazole and its analogs
|
WO1994019346A1
(de)
*
|
1993-02-17 |
1994-09-01 |
Byk Gulden Lomberg Chemische Fabrik Gmbh |
Substituierte heteroarylalkylthiopyridine zur bekämpfung von helicobacter bakterien
|
ES2060541B1
(es)
*
|
1993-02-26 |
1995-11-16 |
Vinas Lab |
Nuevo procedimiento para la sintesis de un derivado de 2-(2-piridilmetilsufinil) bencimidazol, y nuevos productos intermedios obtenidos con el mismo.
|
ES2063705B1
(es)
*
|
1993-06-14 |
1995-07-16 |
S A L V A T Lab Sa |
Intermedio para la sintesis de lansoprazol y su procedimiento de obtencion.
|
SK280159B6
(sk)
*
|
1993-06-29 |
1999-09-10 |
Byk Gulden Lomberg Chemische Fabrik Gmbh |
Substituované aryltioalkyltiopyridíny, spôsob ich
|
TW280770B
(instruction)
*
|
1993-10-15 |
1996-07-11 |
Takeda Pharm Industry Co Ltd |
|
US5374730A
(en)
*
|
1993-11-04 |
1994-12-20 |
Torcan Chemical Ltd. |
Preparation of omeprazole and lansoprazole
|
US5502195A
(en)
*
|
1993-11-04 |
1996-03-26 |
Slemon; Clarke |
Sulfoxide-carboxylate intermediates of omeprazole and lansoprazole
|
CN1048980C
(zh)
*
|
1994-03-29 |
2000-02-02 |
广东汕头鮀滨化学药业总公司 |
一种新的吡啶衍生物及其制备方法和应用
|
CN1070192C
(zh)
*
|
1994-06-10 |
2001-08-29 |
比克·古尔顿·劳姆贝尔格化学公司 |
杀灭螺杆菌用的硫代吡啶
|
SE9402431D0
(sv)
*
|
1994-07-08 |
1994-07-08 |
Astra Ab |
New tablet formulation
|
SE504459C2
(sv)
*
|
1994-07-15 |
1997-02-17 |
Astra Ab |
Förfarande för framställning av substituerade sulfoxider
|
GB9423968D0
(en)
*
|
1994-11-28 |
1995-01-11 |
Astra Ab |
Resolution
|
SE9500422D0
(sv)
*
|
1995-02-06 |
1995-02-06 |
Astra Ab |
New oral pharmaceutical dosage forms
|
SE9500478D0
(sv)
*
|
1995-02-09 |
1995-02-09 |
Astra Ab |
New pharmaceutical formulation and process
|
US5708017A
(en)
*
|
1995-04-04 |
1998-01-13 |
Merck & Co., Inc. |
Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
|
HRP960232A2
(en)
*
|
1995-07-03 |
1998-02-28 |
Astra Ab |
A process for the optical purification of compounds
|
US5824339A
(en)
*
|
1995-09-08 |
1998-10-20 |
Takeda Chemical Industries, Ltd |
Effervescent composition and its production
|
DE69631834T2
(de)
*
|
1995-09-21 |
2005-02-10 |
Pharma Pass Ii Llc, Irvine |
Neues ein säureempfindliches benzimidazol enthaltendes mittel und verfahren zu dessen herstellung
|
SE521100C2
(sv)
*
|
1995-12-15 |
2003-09-30 |
Astra Ab |
Förfarande för framställning av en bensimidazolförening
|
US6645988B2
(en)
*
|
1996-01-04 |
2003-11-11 |
Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and method of using same
|
US5840737A
(en)
|
1996-01-04 |
1998-11-24 |
The Curators Of The University Of Missouri |
Omeprazole solution and method for using same
|
US6699885B2
(en)
*
|
1996-01-04 |
2004-03-02 |
The Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and methods of using same
|
US6489346B1
(en)
*
|
1996-01-04 |
2002-12-03 |
The Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and method of using same
|
SE9600070D0
(sv)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral pharmaceutical dosage forms
|
US8071128B2
(en)
|
1996-06-14 |
2011-12-06 |
Kyowa Hakko Kirin Co., Ltd. |
Intrabuccally rapidly disintegrating tablet and a production method of the tablets
|
US6380222B2
(en)
|
1996-10-11 |
2002-04-30 |
Astrazeneca Ab |
Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
|
TW385306B
(en)
*
|
1996-11-14 |
2000-03-21 |
Takeda Chemical Industries Ltd |
Method for producing crystals of benzimidazole derivatives
|
EP0983263A1
(en)
*
|
1997-05-30 |
2000-03-08 |
Dr. Reddy's Research Foundation |
Novel benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them
|
DE69827392T2
(de)
|
1997-07-25 |
2005-10-27 |
Altana Pharma Ag |
Protonenpumpenhemmer als kombinationstherapeutika mit antibakteriell wirkenden substanzen
|
SE9704870D0
(sv)
*
|
1997-12-22 |
1997-12-22 |
Astra Ab |
New pharmaceutical formulation I
|
KR100554924B1
(ko)
|
1998-05-18 |
2006-03-03 |
다케다 야쿠힌 고교 가부시키가이샤 |
구강내 붕괴 정제
|
ZA9810765B
(en)
*
|
1998-05-28 |
1999-08-06 |
Ranbaxy Lab Ltd |
Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
|
IE990506A1
(en)
*
|
1998-06-26 |
2000-11-15 |
Russinsky Ltd |
Pyridine Building Blocks
|
SI20019A
(sl)
*
|
1998-07-13 |
2000-02-29 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
|
WO2000004904A1
(en)
*
|
1998-07-22 |
2000-02-03 |
Sepracor Inc. |
Pharmaceutical compositions comprising hydroxylansoprazole and uses thereof
|
US6093734A
(en)
*
|
1998-08-10 |
2000-07-25 |
Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin |
Prodrugs of proton pump inhibitors
|
ID28273A
(id)
|
1998-08-10 |
2001-05-10 |
Partnership Of Michael E Garst |
Prodrug inhibitor pompa proton
|
JP4988088B2
(ja)
|
1998-08-12 |
2012-08-01 |
ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ピリジン−2−イルメチルスルフィニル−1h−ベンズイミダゾール、もしくはピリジン−2−イルメチルスルフィニル−1h−ベンズイミダゾールの骨格を有する化合物、またはその薬学的に許容される塩の経口投与形組成物を固定的に組み合わせた組成物
|
DE19843413C1
(de)
*
|
1998-08-18 |
2000-03-30 |
Byk Gulden Lomberg Chem Fab |
Neue Salzform von Pantoprazol
|
JP3926936B2
(ja)
|
1998-11-16 |
2007-06-06 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
スルホキシド誘導体・アセトン錯体およびその製造法
|
US20040224989A1
(en)
*
|
1999-01-29 |
2004-11-11 |
Barberich Timothy J. |
S-lansoprazole compositions and methods
|
US6852739B1
(en)
*
|
1999-02-26 |
2005-02-08 |
Nitromed Inc. |
Methods using proton pump inhibitors and nitric oxide donors
|
TWI243672B
(en)
|
1999-06-01 |
2005-11-21 |
Astrazeneca Ab |
New use of compounds as antibacterial agents
|
PT1187601E
(pt)
|
1999-06-07 |
2005-11-30 |
Altana Pharma Ag |
Nova forma de preparacao e a administracao compreendendo um inibidor da bomba de protoes instavel em meio acido
|
TWI289557B
(en)
|
1999-06-17 |
2007-11-11 |
Takeda Chemical Industries Ltd |
A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
|
US6245913B1
(en)
|
1999-06-30 |
2001-06-12 |
Wockhardt Europe Limited |
Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
|
WO2001002389A1
(fr)
*
|
1999-06-30 |
2001-01-11 |
Takeda Chemical Industries, Ltd. |
Cristaux de composes benzimidazole
|
US6780880B1
(en)
|
1999-08-26 |
2004-08-24 |
Robert R. Whittle |
FT-Raman spectroscopic measurement
|
US6312723B1
(en)
|
1999-08-26 |
2001-11-06 |
Robert R. Whittle |
Pharmaceutical unit dosage form
|
US6262086B1
(en)
|
1999-08-26 |
2001-07-17 |
Robert R. Whittle |
Pharmaceutical unit dosage form
|
US6262085B1
(en)
|
1999-08-26 |
2001-07-17 |
Robert R. Whittle |
Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
|
US6312712B1
(en)
|
1999-08-26 |
2001-11-06 |
Robert R. Whittle |
Method of improving bioavailability
|
US6316020B1
(en)
|
1999-08-26 |
2001-11-13 |
Robert R. Whittle |
Pharmaceutical formulations
|
US6268385B1
(en)
|
1999-08-26 |
2001-07-31 |
Robert R. Whittle |
Dry blend pharmaceutical formulations
|
US6326384B1
(en)
|
1999-08-26 |
2001-12-04 |
Robert R. Whittle |
Dry blend pharmaceutical unit dosage form
|
US6369087B1
(en)
|
1999-08-26 |
2002-04-09 |
Robert R. Whittle |
Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
|
US6228400B1
(en)
|
1999-09-28 |
2001-05-08 |
Carlsbad Technology, Inc. |
Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
|
KR100359256B1
(ko)
*
|
1999-10-06 |
2002-11-04 |
한미약품공업 주식회사 |
란소프라졸의 개선된 제조방법
|
SE9903831D0
(sv)
*
|
1999-10-22 |
1999-10-22 |
Astra Ab |
Formulation of substituted benzimidazoles
|
US20060034937A1
(en)
*
|
1999-11-23 |
2006-02-16 |
Mahesh Patel |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
US20030180352A1
(en)
*
|
1999-11-23 |
2003-09-25 |
Patel Mahesh V. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
US7732404B2
(en)
|
1999-12-30 |
2010-06-08 |
Dexcel Ltd |
Pro-nanodispersion for the delivery of cyclosporin
|
SE0000774D0
(sv)
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
New formulation
|
ES2171116B1
(es)
|
2000-04-14 |
2003-08-01 |
Esteve Quimica Sa |
Procedimiento para la obtencion de derivados de (((piridil sustituido)metil)tio)bencimidazol.
|
CA2701704C
(en)
*
|
2000-05-15 |
2011-09-06 |
Takeda Pharmaceutical Company Limited |
Process for producing crystal
|
CA2775616C
(en)
|
2000-08-04 |
2013-09-17 |
Takeda Pharmaceutical Company Limited |
Salts of benzimidazole compound and application thereof
|
US6544556B1
(en)
|
2000-09-11 |
2003-04-08 |
Andrx Corporation |
Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
|
US20020064555A1
(en)
*
|
2000-09-29 |
2002-05-30 |
Dan Cullen |
Proton pump inhibitor formulation
|
CA2436825C
(en)
|
2000-12-01 |
2011-01-18 |
Takeda Chemical Industries, Ltd. |
Process for the crystallization of (r)- or (s)-lansoprazole
|
ES2380654T3
(es)
|
2000-12-07 |
2012-05-17 |
Nycomed Gmbh |
Tableta de desintegración rápida que comprende un ingrediente activo lábil en medio ácido
|
WO2002045692A1
(en)
|
2000-12-07 |
2002-06-13 |
Altana Pharma Ag |
Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
|
EP1341524B1
(en)
|
2000-12-07 |
2011-10-19 |
Nycomed GmbH |
Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient
|
KR100430575B1
(ko)
*
|
2001-02-21 |
2004-05-10 |
주식회사 씨트리 |
란소프라졸 및 그 중간체의 제조방법
|
US6645946B1
(en)
|
2001-03-27 |
2003-11-11 |
Pro-Pharmaceuticals, Inc. |
Delivery of a therapeutic agent in a formulation for reduced toxicity
|
SE0101379D0
(sv)
|
2001-04-18 |
2001-04-18 |
Diabact Ab |
Komposition som hämmar utsöndring av magsyra
|
US8206741B2
(en)
|
2001-06-01 |
2012-06-26 |
Pozen Inc. |
Pharmaceutical compositions for the coordinated delivery of NSAIDs
|
SE0102993D0
(sv)
|
2001-09-07 |
2001-09-07 |
Astrazeneca Ab |
New self emulsifying drug delivery system
|
WO2003024957A1
(fr)
*
|
2001-09-18 |
2003-03-27 |
Zeria Pharmaceutical Co., Ltd. |
Derives de benzimidazole
|
WO2003027098A1
(fr)
*
|
2001-09-25 |
2003-04-03 |
Takeda Chemical Industries, Ltd. |
Compose de benzymidazole, procede de production et d'utilisation de celui-ci
|
US9358214B2
(en)
|
2001-10-04 |
2016-06-07 |
Adare Pharmaceuticals, Inc. |
Timed, sustained release systems for propranolol
|
US8101209B2
(en)
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
DK1459737T3
(da)
|
2001-10-17 |
2013-01-02 |
Takeda Pharmaceutical |
Granulat indeholdende syreustabilt kemisk middel i stor mængde
|
SE0104295D0
(sv)
*
|
2001-12-18 |
2001-12-18 |
Astrazeneca Ab |
New process
|
RU2215739C1
(ru)
*
|
2002-04-03 |
2003-11-10 |
Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" |
Способ получения 5-метокси-2-(4-метокси-3,5-диметил-2-пиридилметилтио)бензимидазола
|
ATE419840T1
(de)
|
2002-04-09 |
2009-01-15 |
Flamel Tech Sa |
Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
|
ATE407674T1
(de)
|
2002-04-09 |
2008-09-15 |
Flamel Tech Sa |
Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
|
US20030228363A1
(en)
*
|
2002-06-07 |
2003-12-11 |
Patel Mahendra R. |
Stabilized pharmaceutical compositons containing benzimidazole compounds
|
KR100873419B1
(ko)
*
|
2002-06-18 |
2008-12-11 |
페어차일드코리아반도체 주식회사 |
높은 항복 전압, 낮은 온 저항 및 작은 스위칭 손실을갖는 전력용 반도체 소자
|
US6897227B2
(en)
*
|
2002-07-19 |
2005-05-24 |
Winston Pharmaceuticals, Inc. |
Prodrugs of proton pump inhibitors
|
TW200410955A
(en)
|
2002-07-29 |
2004-07-01 |
Altana Pharma Ag |
Novel salt of (S)-PANTOPRAZOLE
|
US7211590B2
(en)
*
|
2002-08-01 |
2007-05-01 |
Nitromed, Inc. |
Nitrosated proton pump inhibitors, compositions and methods of use
|
DE60316791T2
(de)
*
|
2002-08-21 |
2008-07-24 |
Teva Pharmaceutical Industries Ltd. |
Verfahren zur aufreinigung von lanzoprazol
|
EP2295062B1
(en)
|
2002-08-30 |
2012-08-29 |
Nycomed GmbH |
The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
|
SE0203065D0
(sv)
|
2002-10-16 |
2002-10-16 |
Diabact Ab |
Gastric acid secretion inhibiting composition
|
MY148805A
(en)
|
2002-10-16 |
2013-05-31 |
Takeda Pharmaceutical |
Controlled release preparation
|
EP2596792A1
(en)
*
|
2002-10-16 |
2013-05-29 |
Takeda Pharmaceutical Company Limited |
Stable solid preparations
|
PT1465890E
(pt)
*
|
2002-11-18 |
2007-05-31 |
Teva Pharma |
Lansoprazole estável contendo mais de 500 ppm, até cerca de 3000 ppm de água e mais de 200 ppm, até cerca de 5000 de álcool
|
EP1743893A1
(en)
|
2002-11-18 |
2007-01-17 |
Teva Pharmaceutical Industries Ltd. |
Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol
|
DE10254167A1
(de)
|
2002-11-20 |
2004-06-09 |
Icon Genetics Ag |
Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
|
CN100482658C
(zh)
|
2002-12-06 |
2009-04-29 |
尼可姆公司 |
制备光学纯活性化合物的方法
|
JP2006514985A
(ja)
|
2002-12-06 |
2006-05-18 |
アルタナ ファルマ アクチエンゲゼルシャフト |
(s)−パントプラゾールの製造方法
|
WO2004056804A2
(en)
*
|
2002-12-19 |
2004-07-08 |
Teva Pharmaceutical Industries Ltd. |
Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
|
US8367111B2
(en)
|
2002-12-31 |
2013-02-05 |
Aptalis Pharmatech, Inc. |
Extended release dosage forms of propranolol hydrochloride
|
CA2515130A1
(en)
*
|
2003-02-05 |
2004-08-26 |
Teva Pharmaceutical Industries Ltd. |
Method of stabilizing lansoprazole
|
US20050220870A1
(en)
*
|
2003-02-20 |
2005-10-06 |
Bonnie Hepburn |
Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
|
ES2245277T1
(es)
*
|
2003-03-12 |
2006-01-01 |
Teva Pharmaceutical Industries Limited |
Solidos cristalinos y amorfos de pantoprazol y procedimientos para su preparacion.
|
EP1602362B1
(en)
*
|
2003-03-12 |
2016-09-28 |
Takeda Pharmaceutical Company Limited |
Drug composition having active ingredient adhered at high concentration to spherical core
|
US7608625B2
(en)
*
|
2003-03-13 |
2009-10-27 |
Eisai R & D Management Co., Ltd. |
Method for treating bruxism and bruxism-related diseases
|
US20050031696A1
(en)
*
|
2003-04-22 |
2005-02-10 |
Dr. Reddy's Laboratories Limited |
Oral pharmaceutical formulations of acid-labile active ingredients and process for making same
|
CL2004000983A1
(es)
|
2003-05-08 |
2005-03-04 |
Altana Pharma Ag |
Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
|
PE20050150A1
(es)
|
2003-05-08 |
2005-03-22 |
Altana Pharma Ag |
Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
|
EP1615913A2
(en)
*
|
2003-06-10 |
2006-01-18 |
Teva Pharmaceutical Industries Limited |
Process for preparing 2-(pyridinyl)methyl sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
|
CA2529984C
(en)
|
2003-06-26 |
2012-09-25 |
Isa Odidi |
Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
|
CA2532104A1
(en)
*
|
2003-07-15 |
2005-02-24 |
Allergan, Inc. |
Process for preparing isomerically pure prodrugs of proton pump inhibitors
|
US8993599B2
(en)
|
2003-07-18 |
2015-03-31 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
JP2007504261A
(ja)
*
|
2003-09-03 |
2007-03-01 |
エイジーアイ・セラピューティクス・リサーチ・リミテッド |
プロトンポンプ阻害剤製剤、並びに当該製剤を製造及び使用する方法関連出願の表示
|
TWI372066B
(en)
|
2003-10-01 |
2012-09-11 |
Wyeth Corp |
Pantoprazole multiparticulate formulations
|
US20060241037A1
(en)
*
|
2003-10-03 |
2006-10-26 |
Allergan Inc. |
Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump ihhibitor prodrugs
|
US20050075371A1
(en)
*
|
2003-10-03 |
2005-04-07 |
Allergan, Inc. |
Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
|
JP2007522217A
(ja)
*
|
2004-02-10 |
2007-08-09 |
サンタラス インコーポレイティッド |
プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
|
GB0403165D0
(en)
*
|
2004-02-12 |
2004-03-17 |
Ct |
Novel uses for proton pump inhibitors
|
BRPI0507837A
(pt)
*
|
2004-02-18 |
2007-07-10 |
Allergan Inc |
métodos e composições para a administração intravenosa de compostos relacionados a inibidores de bomba de prótons
|
BRPI0507784A
(pt)
*
|
2004-02-18 |
2007-07-17 |
Allergan Inc |
métodos e composições para a administração de pró-fármacos de inibidores da bomba de prótons
|
EP1720527A2
(en)
*
|
2004-03-03 |
2006-11-15 |
Teva Pharmaceutical Industries Ltd |
A stable pharmaceutical composition comprising an acid labile drug
|
WO2005117870A2
(en)
*
|
2004-04-16 |
2005-12-15 |
Santarus, Inc. |
Combination of proton pump inhibitor, buffering agent, and prokinetic agent
|
EP1742946A1
(en)
*
|
2004-04-28 |
2007-01-17 |
Altana Pharma AG |
Dialkoxy-imidazopyridines derivatives
|
US8815916B2
(en)
|
2004-05-25 |
2014-08-26 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
US8906940B2
(en)
|
2004-05-25 |
2014-12-09 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
CA2570916C
(en)
|
2004-06-16 |
2013-06-11 |
Tap Pharmaceutical Products, Inc. |
Pulsed release dosage form of a ppi
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
US20060024362A1
(en)
*
|
2004-07-29 |
2006-02-02 |
Pawan Seth |
Composition comprising a benzimidazole and process for its manufacture
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
EP2264025B1
(en)
|
2004-09-13 |
2013-11-06 |
Takeda Pharmaceutical Company Limited |
Method for producing lansoprazole
|
US8747895B2
(en)
|
2004-09-13 |
2014-06-10 |
Aptalis Pharmatech, Inc. |
Orally disintegrating tablets of atomoxetine
|
US9884014B2
(en)
|
2004-10-12 |
2018-02-06 |
Adare Pharmaceuticals, Inc. |
Taste-masked pharmaceutical compositions
|
AU2005299490C1
(en)
|
2004-10-21 |
2012-01-19 |
Adare Pharmaceuticals, Inc. |
Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
|
US20060105038A1
(en)
*
|
2004-11-12 |
2006-05-18 |
Eurand Pharmaceuticals Limited |
Taste-masked pharmaceutical compositions prepared by coacervation
|
KR20070109985A
(ko)
|
2004-11-22 |
2007-11-15 |
아나디스 리미티드 |
생물활성 조성물
|
EP1681056A1
(en)
|
2005-01-14 |
2006-07-19 |
Krka Tovarna Zdravil, D.D., Novo Mesto |
Process for preparing lansoprazole
|
ES2675581T3
(es)
|
2005-02-25 |
2018-07-11 |
Takeda Pharmaceutical Company Limited |
Método para producir gránulos de un compuesto de bencimidazol recubiertos
|
KR100771659B1
(ko)
|
2005-03-23 |
2007-10-30 |
주식회사 카이로제닉스 |
판토프라졸 및 그 중간체의 제조방법
|
US9161918B2
(en)
|
2005-05-02 |
2015-10-20 |
Adare Pharmaceuticals, Inc. |
Timed, pulsatile release systems
|
US7803817B2
(en)
|
2005-05-11 |
2010-09-28 |
Vecta, Ltd. |
Composition and methods for inhibiting gastric acid secretion
|
US7981908B2
(en)
|
2005-05-11 |
2011-07-19 |
Vecta, Ltd. |
Compositions and methods for inhibiting gastric acid secretion
|
WO2006132217A1
(ja)
|
2005-06-07 |
2006-12-14 |
Takeda Pharmaceutical Company Limited |
ベンズイミダゾール化合物の塩の結晶
|
CA2611917A1
(en)
*
|
2005-06-13 |
2006-12-21 |
Takeda Pharmaceutical Company Limited |
Injection
|
US7601737B2
(en)
|
2005-07-26 |
2009-10-13 |
Nycomed Gmbh |
Isotopically substituted proton pump inhibitors
|
BRPI0617987A2
(pt)
*
|
2005-10-06 |
2011-08-16 |
Auspex Pharmaceuticals Inc |
composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico
|
GB0525710D0
(en)
*
|
2005-12-17 |
2006-01-25 |
Pliva Hrvatska D O O |
An improved process for preparing of substituted 2-benzimidazolesulfoxide compounds
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
US8486450B2
(en)
|
2005-12-28 |
2013-07-16 |
Takeda Pharmaceutical Company Limited |
Method of producing solid preparation disintegrating in the oral cavity
|
KR20080081071A
(ko)
|
2005-12-28 |
2008-09-05 |
다케다 야쿠힌 고교 가부시키가이샤 |
방출 제어 고형 제제
|
CA2645467C
(en)
*
|
2006-03-10 |
2012-04-24 |
Arigen Pharmaceuticals, Inc. |
Pyridine derivative having anti-helicobacter pylori activity
|
EP2007360B1
(en)
|
2006-04-03 |
2014-11-26 |
Isa Odidi |
Controlled release delivery device comprising an organosol coat
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
AU2007266574A1
(en)
*
|
2006-06-01 |
2007-12-06 |
Dexcel Pharma Technologies Ltd. |
Multiple unit pharmaceutical formulation
|
US7863330B2
(en)
*
|
2006-06-14 |
2011-01-04 |
Rottapharm S.P.A. |
Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
|
JP5474541B2
(ja)
|
2006-07-25 |
2014-04-16 |
ベクタ・リミテッド |
小さいジカルボン酸の誘導体と組み合わせてppiを用いる胃酸分泌を阻害する組成物および方法
|
WO2008036201A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Alevium Pharmaceuticals, Inc. |
Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
|
WO2008035189A1
(en)
*
|
2006-09-22 |
2008-03-27 |
Orchid Chemicals & Pharmaceuticals Limited |
A method for the purification of lansoprazole
|
GB2459393B
(en)
|
2006-10-05 |
2010-09-08 |
Santarus Inc |
Novel capsule formulation for the proton pump inhibitor omeprazole
|
US20080103169A1
(en)
|
2006-10-27 |
2008-05-01 |
The Curators Of The University Of Missouri |
Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
|
EP2478895A3
(en)
|
2006-12-22 |
2012-12-19 |
Ironwood Pharmaceuticals, Inc. |
Compositions for treating esophageal disorders
|
JP5366558B2
(ja)
|
2006-12-28 |
2013-12-11 |
武田薬品工業株式会社 |
口腔内崩壊性固形製剤
|
WO2008087665A2
(en)
*
|
2007-01-18 |
2008-07-24 |
Matrix Laboratories Ltd |
Process for preparation of lansoprazole
|
US20080194307A1
(en)
*
|
2007-02-13 |
2008-08-14 |
Jeff Sanger |
Sports-based game of chance
|
TW200840574A
(en)
*
|
2007-04-02 |
2008-10-16 |
Univ Nat Taiwan |
The pharmaceutical component for treating hearing loss disease
|
US20100210847A1
(en)
*
|
2007-07-17 |
2010-08-19 |
Ranbaxy Laboratories Limited |
Process for the preparation of pantoprazole sodium and pantoprazole sodium sesquihydrate
|
CN104069088A
(zh)
|
2007-10-12 |
2014-10-01 |
武田制药北美公司 |
与食物摄入无关的治疗胃肠病症的方法
|
NZ593629A
(en)
*
|
2007-12-18 |
2012-11-30 |
Watson Pharma Private Ltd |
Stable amorphous R-lansoprazole prepared by optically resolving racemic lansoprazole
|
EP2292612A3
(en)
|
2007-12-31 |
2011-05-04 |
Takeda Pharmaceutical Company Limited |
Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
|
WO2009105568A1
(en)
|
2008-02-20 |
2009-08-27 |
The Curators Of The University Of Missouri |
Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
|
US20090227633A1
(en)
*
|
2008-03-04 |
2009-09-10 |
Bassam Damaj |
Methods to inhibit tumor cell growth by using proton pump inhibitors
|
AR070972A1
(es)
|
2008-03-10 |
2010-05-19 |
Takeda Pharmaceutical |
Cristal de compuestos de bencimidazol (lansoprazol)
|
US20090263475A1
(en)
*
|
2008-04-21 |
2009-10-22 |
Nagaraju Manne |
Dexlansoprazole compositions
|
WO2010079504A2
(en)
|
2008-05-14 |
2010-07-15 |
Watson Pharma Private Limited |
Stable r(+)-lansoprazole amine salt and a process for preparing the same
|
EA201100313A1
(ru)
|
2008-09-09 |
2011-10-31 |
Астразенека Аб |
Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
|
WO2010039885A2
(en)
*
|
2008-09-30 |
2010-04-08 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of dexlansoprazole
|
US20100093747A1
(en)
*
|
2008-10-10 |
2010-04-15 |
Erica Brook Goodhew |
Method of inducing negative chemotaxis
|
US11304960B2
(en)
|
2009-01-08 |
2022-04-19 |
Chandrashekar Giliyar |
Steroidal compositions
|
WO2010122583A2
(en)
|
2009-04-24 |
2010-10-28 |
Rubicon Research Private Limited |
Oral pharmaceutical compositions of acid labile substances
|
WO2010134099A1
(en)
|
2009-05-21 |
2010-11-25 |
Cadila Healthcare Limited |
One pot process for preparing omeprazole and related compounds
|
WO2011004387A2
(en)
|
2009-06-18 |
2011-01-13 |
Matrix Laboratories Ltd |
Process for the preparation of dexlansoprazole polymorphic forms
|
SG176724A1
(en)
|
2009-06-25 |
2012-01-30 |
Astrazeneca Ab |
Method for treating a patient at risk for developing an nsaid-associated ulcer
|
MX2012006240A
(es)
|
2009-12-02 |
2012-10-03 |
Aptalis Pharma Ltd |
Microcapsulas de fexofenadina y composiciones que contienen las mismas.
|
EP2519229A2
(en)
|
2009-12-29 |
2012-11-07 |
Novartis AG |
New pharmaceutical dosage form for the treatment of gastric acid-related disorders
|
WO2011080502A2
(en)
|
2009-12-29 |
2011-07-07 |
Orexo Ab |
New pharmaceutical dosage form for the treatment of gastric acid-related disorders
|
WO2011080500A2
(en)
|
2009-12-29 |
2011-07-07 |
Orexo Ab |
New pharmaceutical dosage form for the treatment of gastric acid-related disorders
|
UY33173A
(instruction)
*
|
2010-01-08 |
2011-07-29 |
Eurand Inc |
|
US20110189271A1
(en)
*
|
2010-02-02 |
2011-08-04 |
Vishal Lad |
Pharmaceutical formulations of acid-labile drugs
|
US20130202688A1
(en)
|
2010-05-04 |
2013-08-08 |
Sunilendu Bhushan Roy |
Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
|
WO2012001705A2
(en)
|
2010-06-29 |
2012-01-05 |
Cadila Healthcare Limited |
Pharmaceutical compositions of (r)-lansoprazole
|
WO2012027331A1
(en)
|
2010-08-27 |
2012-03-01 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
US9034858B2
(en)
|
2010-11-30 |
2015-05-19 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US20180153904A1
(en)
|
2010-11-30 |
2018-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US9358241B2
(en)
|
2010-11-30 |
2016-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
WO2012074110A1
(ja)
|
2010-12-03 |
2012-06-07 |
武田薬品工業株式会社 |
口腔内崩壊錠
|
US20120148675A1
(en)
|
2010-12-10 |
2012-06-14 |
Basawaraj Chickmath |
Testosterone undecanoate compositions
|
KR20140007364A
(ko)
|
2010-12-27 |
2014-01-17 |
다케다 야쿠힌 고교 가부시키가이샤 |
구강내 붕괴정
|
US9233103B2
(en)
|
2011-03-25 |
2016-01-12 |
Takeda Pharmaceuticals U.S.A., Inc. |
Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
|
ES2561098T3
(es)
|
2011-11-30 |
2016-02-24 |
Takeda Pharmaceutical Company Limited |
Comprimido recubierto en seco
|
EP2601947A1
(en)
|
2011-12-05 |
2013-06-12 |
Abo Bakr Mohammed Ali Al-Mehdar |
Fixed-dose combination for treatment of helicobacter pylori associated diseases
|
WO2013088109A1
(en)
|
2011-12-16 |
2013-06-20 |
Oxagen Limited |
Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
|
WO2013101897A2
(en)
|
2011-12-28 |
2013-07-04 |
Pozen Inc. |
Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
|
WO2013108068A1
(en)
|
2012-01-21 |
2013-07-25 |
Jubilant Life Sciences Limited |
Process for the preparation of 2-pyridinylmethylsulfinyl benzimidazoles, their analogs and optically active enantiomers
|
AU2014207680B2
(en)
|
2013-01-15 |
2018-09-06 |
Ironwood Pharmaceuticals, Inc. |
Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant
|
MY184077A
(en)
|
2013-05-21 |
2021-03-17 |
Takeda Pharmaceuticals Co |
Orally disintegrable tablet
|
US9457011B2
(en)
|
2014-02-25 |
2016-10-04 |
Muslim D. Shahid |
Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor
|
WO2016033556A1
(en)
|
2014-08-28 |
2016-03-03 |
Lipocine Inc. |
BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
|
WO2016033549A2
(en)
|
2014-08-28 |
2016-03-03 |
Lipocine Inc. |
(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
|
WO2016126625A1
(en)
|
2015-02-03 |
2016-08-11 |
Ironwood Pharmaceuticals, Inc. |
Methods of treating upper gastrointestinal disorders in ppi refractory gerd
|
US20170042806A1
(en)
|
2015-04-29 |
2017-02-16 |
Dexcel Pharma Technologies Ltd. |
Orally disintegrating compositions
|
US20160361322A1
(en)
|
2015-06-15 |
2016-12-15 |
Lipocine Inc. |
Composition and method for oral delivery of androgen prodrugs
|
WO2017145146A1
(en)
|
2016-02-25 |
2017-08-31 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising proton pump inhibitors
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
EP3544614A4
(en)
|
2016-11-28 |
2020-08-05 |
Lipocine Inc. |
TESTOSTERONE UNDECANOATE ORAL TREATMENT
|
CN107365300B
(zh)
*
|
2017-07-26 |
2019-08-02 |
桂林华信制药有限公司 |
一种有效去除兰索拉唑粗品中杂质的方法
|
US12150945B2
(en)
|
2018-07-20 |
2024-11-26 |
Lipocine Inc. |
Liver disease
|
CN114163419A
(zh)
*
|
2021-12-24 |
2022-03-11 |
辰欣药业股份有限公司 |
一种兰索拉唑的制备方法
|
EP4598528A1
(en)
|
2022-10-04 |
2025-08-13 |
Arsenil Zabirnyk |
Inhibition of aortic valve calcification
|